Edition:
Deutschland

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

71.42USD
18 Jan 2019
Change (% chg)

$0.90 (+1.28%)
Prev Close
$70.52
Open
$70.91
Day's High
$71.74
Day's Low
$70.78
Volume
3,018,980
Avg. Vol
1,990,673
52-wk High
$74.91
52-wk Low
$55.59

ABT.N

Chart for ABT.N

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Buy/Sell

Sell Hold Buy
1.81 Mean rating from 21 analysts

Overall

Beta: 1.57
Market Cap(Mil.): $95,559.38
Shares Outstanding(Mil.): 1,737.44
Dividend: 0.26
Yield (%): 1.93

CORRECTED-FOCUS-U.S. regulators snip red tape for medical devices to curb opioid crisis

Nov 9 Laura Perryman expected her medical company, Stimwave Technologies Inc, would have to wait several years for its painkilling device to win U.S. approval as a treatment for chronic migraines.

FOCUS-U.S. regulators snip red tape for medical devices to curb opioid crisis

Nov 9 Laura Perryman expected her medical company, Stimwave Technologies Inc, would have to wait several years for its painkilling device to win U.S. approval as a treatment for chronic migraines.

UPDATE 2-Abbott, AbbVie settle TriCor marketing case for $25 mln

Oct 26 Abbott Laboratories and AbbVie Inc will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.

Abbott, AbbVie settle U.S. case over TriCor marketing for $25 mln

Oct 26 Abbott Laboratories and AbbVie Inc will pay $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for them prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.

Photo

AbbVie CFO Chase to retire by mid-year 2019

AbbVie Inc said on Friday that William Chase stepped down as chief financial officer and will retire from the company in mid-2019, and the U.S. drugmaker promoted controller, Robert Michael, to the CFO role.

UPDATE 2-AbbVie CFO Chase to retire by mid-year 2019

Oct 19 AbbVie Inc said on Friday that William Chase stepped down as chief financial officer and will retire from the company in mid-2019, and the U.S. drugmaker promoted controller, Robert Michael, to the CFO role.

Photo

Abbott Labs quarterly profit falls on higher tax expense

Abbott Laboratories reported a 6.6 percent drop in quarterly profit on Wednesday, hurt by higher tax expense on earnings.

UPDATE 1-Abbott Labs quarterly profit falls on higher tax expense

Oct 17 Abbott Laboratories reported a 6.6 percent drop in quarterly profit on Wednesday, hurt by higher tax expense on earnings.

Abbott Labs quarterly profit falls 6.6 pct on tax expense

Oct 17 Diversified healthcare company Abbott Laboratories reported a 6.6 percent drop in quarterly profit on Wednesday, hurt by higher tax expense on earnings.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +1.07%
Rohstoffe +1.47%
Industrie +1.01%
Konjunktur abhängige Waren & Dienstleistungen +1.02%
Konjunktur unabhängige Waren & Dienstleistungen +1.19%
Finanzindustrie +0.97%
Pharma +1.31%
Technologie +0.57%
Telekommunikation +0.30%

Nachrichten aus der Wirtschaft